Skip to Content
Søg Menu

Highlights fra ASCO GU 2024 om blærekræft i en dansk kontekst

Dag Rune Stormoen, læge og ph.d.-studerende, Afdeling for Kræftbehandling, Rigshospitalet, præsenterer i denne MEDtalk, hvilke nye data om blærecancer, han tager med hjem fra ASCO GU 2024.
Dag Rune Stormoen

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Joaquim Bellmunt

First-Line Maintenance Therapy with Avelumab Show Significantly Prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden

/ Joaquim Bellmunt
ASCO24Blærecancer Play the Video 5:36
Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatacancer Play the Video 1:31
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrecancer Play the Video 1:47
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrecancer Play the Video 2:21
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrecancer Play the Video 2:46
Jakob Lauritsen

Highlights fra ASCO GU 2024 om prostatacancer i en dansk kontekst

/ Jakob Lauritsen
ASCOGU24Prostatacancer Play the Video 4:21
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrecancer Play the Video 3:16
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærecancer Play the Video 2:14

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

/ Sofie Pohl
ASCOGU24Nyrecancer
Back to top